CDKN1B inactivation impacts ER signaling and drives resistance to endocrine therapy in breast cancer. Ahmad S, Butle A, Karn A, Sunder R, et al. Br J Cancer 2026 Apr 22. doi: 10.1038/s41416-026-03388.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ahmad S, Butle A, Karn A, Sunder R, et al. CDKN1B inactivation impacts ER signaling and drives resistance to endocrine therapy in breast cancer. Br J Cancer 2026 Apr 22. doi: 10.1038/s41416-026-03388.
PMID: 42020778